clopidrogel: Anti-coaugulant
Het is een prodrug--> bindt zich aan ADP receptoren op bloedplaatjes--> blokkade--> geen aggregatie van plaatjes en linking met fibrine.
CYP2C19 is an important drug-metabolizing enzyme that catalyzes the biotransformation of Clopidogrel. CYP2C19 poor metabolizers, representing up to 14% of patients, are at high risk of treatment failure and that testing is available and a 3.58 times greater risk for major adverse cardiovascular events such as death, heart attack, and stroke; the risk was greatest in CYP2C19 poor metabolizers.